

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 2

APPLICATION NO.: 10/616,409

ATTY. DOCKET NO.: 10248.70024US00

FILING DATE: July 9, 2003

CONFIRMATION NO.: 9289

APPLICANT: Adams et al.

GROUP ART UNIT: 1645

EXAMINER: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2003/0130199	A1	von Hoersten et al.	07-10-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
BF		WO	03/002595	A2	Probiodrug AG et al.	01-09-2003	


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
BF		Press Release, Point Therapeutics, "Point Therapeutics Announces Positive Results in Phase 2: Metastatic Melanoma Program," May 14, 2005, 3 pages.		
BF		Press Release, Point Therapeutics, "Point Therapeutics Presents Positive Results in Phase 2: Talabostat Non-Small Cell Lung Cancer Study," May 17, 2005, 3 pages.		
BF		ADAMS et al., "Enhanced Anti-Tumor Activity of Dipeptidyl Peptidase Inhibitor PT-100 in Combination with Chemotherapy in Mice," American Association of Cancer Research (AACR) Annual Meeting, Orlando, Florida, March 27-31, 2004, Poster 3820.		
		CUNNINGHAM et al., "Phase 2 Study of Talabostat and Cisplatin in Stage IV Melanoma," American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Florida, May 14, 2005, Abstract 7563.		
		CUNNINGHAM et al., "Phase 2 Trial of Talabostat and Docetaxel in Patients with Stage IIIB/IV NSCLC," American Society of Clinical Oncology (ASCO) Annual Meeting, May 17, 2005, Poster 7120.		

Brandon Fentie 10/11/2005

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: I0248.70024US00		
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289		
				APPLICANT: Adams et al.				
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned		
Sheet	2	of	2					

		NEMUNAITIS et al., "A Phase I Trial of Talabostat (PT-100) in Patients Receiving Myelosuppressive Chemotherapy," American Society of Clinical Oncology (ASCO) Annual Meeting, New Orleans, Louisiana, June 5-8, 2004, Poster 2572.		
		REDMAN et al., "Phase 2 Trial of Talabostat in Stage IV Melanoma," American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Florida, May 14, 2005, Abstract 7570.		

EXAMINER:	DATE CONSIDERED:
	10/11/2005

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

EXAMINER: Not Yet Assigned

Sheet	1	of	4
-------	---	----	---

Brandon Williams 10/11/2008

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned	
Sheet	2	of	4				

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
BF	B4	WO	89/03223	A1	Bachovchin et al.	04-20-1989	
BF	B5	WO	91/16339	A1	New England Medical Center Hospitals, Inc.	10-31-1991	
BF	B6	WO	91/17767	A1	New England Medical Center Hospitals, Inc.	11-28-1991	
BF	B7	WO	92/12140	A1	Georgia Tech Research Corporation	07-23-1992	
BF	B8	WO	93/08259	A2	New England Medical Center Hospitals, Inc.	04-29-1993	
BF	B9	WO	93/10127	A1	Boehringer Ingelheim Pharmaceuticals, Inc.	05-27-1993	
BF	B10	WO	93/16102	A1	Dana-Farber Cancer Institute	08-19-1993	
BF	B11	WO	94/03055	A1	The Government of the United States of America	02-17-1994	
BF	B12	WO	94/09132	A1	Dana-Farber Cancer Institute	04-28-1994	
BF	B13	WO	95/11689	A1	Trustees of Tufts College	05-04-1995	
BF	B14	WO	95/15309	A1	Ferring B.V.	06-08-1995	
BF	B15	WO	98/00439	A2	Trustees of Tufts College	01-08-1998	
BF	B16	WO	98/50046	A1	Trustees of Tufts College	11-12-1998	
BF	B17	WO	98/50066	A1	Trustees of Tufts College	11-12-1998	
BF	B18	WO	99/16864	A1	Point Therapeutics, Inc.	04-08-1999	
BF	B19	WO	99/56753	A1	Point Therapeutics, Inc.	11-11-1999	
BF	B20	WO	99/62914	A1	Point Therapeutics, Inc.	12-09-1999	
BF	B21	WO	00/10549	A1	Point Therapeutics, Inc.	03-02-2000	
BF	B22	WO	00/71135	A1	Point Therapeutics, Inc.	11-30-2000	
BF	B23	WO	2004/004658	A2	Point Therapeutics, Inc.	01-15-2004	
BF		WO	2004/004661	A2	Point Therapeutics, Inc.	01-15-2004	

REJ

?
as ADOS
ADOS
Tanner
- Targeting
Tumor

As same
has compound
-
Character

X

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
BF	C1	BAKER et al., Hydroxamates and aliphatic boronic acids: marker inhibitors for aminopeptidase. Biochemistry. 1983 Apr 26;22(9):2098-103.		
BF	C2	BORLOO et al., Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors. Verh K Acad Geneesk Belg. 1994;56(1):57-88.		
BF	C3	HEGEN et al., The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol. 1990 Apr 15;144(8):2908-14. Abstract Only.		
BF	C4	JIANG et al., Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res Virol. 1997 Jul-Aug;148(4):255-66.		
BF	C5	KELLY et al., Immunosuppressive boronic acid dipeptides: correlation between conformation and activity. J Am Chem Soc. 1993;115:12637-8.		
BF	C6	KELLY et al., The efficient synthesis and simple resolution of a proline boronate ester suitable for enzyme inhibition studies. Tetrahedron. 1993;49:1009-16.		

[Handwritten signature]

10/11/2002

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned	
Sheet	3	of	4				


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
bf	C7	KETTNER et al., Kinetic properties of the binding of alpha-lytic protease to peptide boronic acids. Biochemistry. 1988 Oct 4;27(20):7682-8.	
bf	C8	KETTNER et al., Peptide boronic acid inhibitors of trypsin-like proteases, their preparation and use as anticoagulants and inflammation inhibitors. Chemical Abstracts. 1990;112:80. Abstract number 91790c.	
bf	C9	KINDER et al., Antimetastatic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Invasion Metastasis. 1992;12(5-6):309-19.	
bf	C10	KINDER et al., Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine. J Med Chem. 1990 Feb;33(2):819-23.	
bf	C11	KINDER et al., Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase. J Med Chem. 1985 Dec;28(12):1917-25.	
bf	C12	KUBOTA et al., Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol. 1992 Aug;89(2):192-7.	
bf	C13	KUBOTA et al., Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol. 1994 May;96(2):292-6.	
bf	C14	REINHOLD et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett. 1997 Jun;58(1):29-35.	
bf	C15	SCANLAN et al., Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61.	
bf	C16	SCHARPE et al., Purified and cell-bound CD26: enzymatic inhibition, antibody binding profile, and expression on T cells in relation to other surface markers. Verh K Acad Geneesk Belg. 1994;56(6):537-59.	
bf	C17	SCHON et al., Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol Chem Hoppe Seyler. 1991 May;372(5):305-11.	
bf	C18	SCHON et al., The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta. 1985;44(2):K9-15. Abstract Only.	
bf	C19	SCHON et al., Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. Biomed Biochim Acta. 1986;45(11-12):1523-8. Abstract Only.	
bf	C20	SCHON et al., The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol. 1987 Dec;17(12):1821-6. Abstract Only.	
bf	C21	SNOW et al., Studies on Proline Boronic Acid Dipeptide Inhibitors of Dipeptidyl Peptidase IV: Identification of a Cyclic Species Containing a B-N Bond. J Am Chem Soc. 1994;116:10860-9.	
bf	C22	SUBRAMANYAM et al., Chapter 9: CD26, a T-cell accessory molecule induction of antigen-specific immune-sppression by inactivations of CD26: A clue to the AIDS paradox? in Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response, edited by Bernhard Fleischer. 1995: R.G. Landes Company, p155-62.	
bf	C23	TANAKA et al., Cloning and functional expression of the T cell activation antigen CD26. J Immunol. 1992 Jul 15;149(2):481-6. Erratum in: J Immunol. 1993 Mar 1;150(5):2090.	
bf	C24	TANAKA et al., The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4586-90. Abstract Only.	
bf	C25	THOMPSON et al., Chapter 19: Peptide aldehydes: potent inhibitors of serine and cysteine proteases. in Methods in Enzymology, Volume 46. Colowick et al., eds. p220-5.	

Barbara W. W.

10/11/2006

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1645		EXAMINER: Not Yet Assigned	
Sheet	4	of	4				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
JK	C26	WELCH et al., Fluoroolefin containing dipeptide isosteres as inhibitors of dipeptidyl peptidase IV(CD26): Tetrahedron. 1996 January 1;52(1):291-304.		
JK	C27	WESLEY et al., A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999 Aug 2;190(3):311-22.		
JK	C28	WOOD et al., Tetrapeptide inhibitors of the IgA1 proteinases from type I Neisseria gonorrhoeae. J Med Chem. 1989 Oct;32(10):2407-11.		
JK	C29	YOSHIMOTO et al., Comparison of inhibitory effects of prolinal-containing peptide derivatives on prolyl endopeptidases from bovine brain and Flavobacterium. J Biochem (Tokyo). 1985 Oct;98(4):975-9.		

EXAMINER: 	DATE CONSIDERED: 10/11/2005
---	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]